kemalbas/iStock via Getty Images
Innovent Biologics (OTCPK:IVBIY) announced that Chinese regulators approved its second marketing application for lung cancer therapy, Dovbleron, developed with US biotech Nuvation Bio (NYSE:NUVB).
The Chinese biotech company announced late Thursday that China's National Medical Products Administration (NMPA) has approved Innovent's (